

Sarah E Church

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5838687/publications.pdf>

Version: 2024-02-01

17
papers

4,411
citations

566801

15
h-index

887659

17
g-index

17
all docs

17
docs citations

17
times ranked

7678
citing authors

#	ARTICLE	IF	CITATIONS
1	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <i>Lancet, The</i> , 2018, 391, 2128-2139.	6.3	1,487
2	Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. <i>Immunity</i> , 2016, 44, 698-711.	6.6	814
3	Multiplex digital spatial profiling of proteins and RNA in fixed tissue. <i>Nature Biotechnology</i> , 2020, 38, 586-599.	9.4	509
4	The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. <i>Science Translational Medicine</i> , 2016, 8, 327ra26.	5.8	360
5	The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients. <i>Cancer Cell</i> , 2018, 34, 1012-1026.e3.	7.7	209
6	Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival. <i>Journal of the National Cancer Institute</i> , 2018, 110, 97-108.	3.0	199
7	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. <i>Blood</i> , 2021, 137, 751-762.	0.6	183
8	PSMA-targeting TGF β -insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. <i>Nature Medicine</i> , 2022, 28, 724-734.	15.2	171
9	Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	117
10	Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. <i>Nature Medicine</i> , 2022, 28, 1256-1268.	15.2	105
11	TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. <i>Blood Advances</i> , 2020, 4, 5011-5024.	2.5	85
12	Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse. <i>Immunity</i> , 2015, 43, 631-633.	6.6	50
13	Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx [®] Digital Spatial Profiler. <i>Cancers</i> , 2021, 13, 4456.	1.7	50
14	Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 187-202.	1.1	24
15	Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 \times CD3 Bispecific Dart [®] Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 444-444.	0.6	18
16	The tumor immune microenvironment of primary and metastatic HER2 ⁺ positive breast cancers utilizing gene expression and spatial proteomic profiling. <i>Journal of Translational Medicine</i> , 2021, 19, 480.	1.8	17
17	Two Patients With Advanced-Stage Lung Adenocarcinoma With Radiologic Complete Response to Nivolumab Treatment Harboring an <i>STK11</i> / <i>LKB1</i> Mutation. <i>JCO Precision Oncology</i> , 2020, 4, 1239-1245.	1.5	13